Skip to content
Injecting

Subcutaneous injection sites and how to rotate them

Where to give a subcutaneous (subQ) injection, how far apart to space them, how to rotate sites, and how to avoid lumps under the skin (lipohypertrophy).

Medical review in progressLast reviewed 6 min read

The usual subcutaneous (subQ) injection sites are the belly (at least 2 inches, or 5 cm, from the belly button), the outer upper thighs and the back or side of the upper arms; some guidance also includes the buttocks. Rotate so that each injection is at least 1 inch (2.5 cm) from the last, because injecting the same spot again and again can cause lumpy fatty tissue, called lipohypertrophy, that absorbs medicine unevenly. Before you inject, the syringe reader shows where your draw sits on a 30, 50 or 100-unit syringe.

The sites

SiteWhere exactlyNotes
BellyBelow the ribs, above the hip bones, at least 2 in (5 cm) from the belly buttonThe largest area, so the easiest to rotate across
ThighsUpper thigh, on the outer sideEasy to reach yourself
Upper armsBack or side, at least 3 in (7.6 cm) below the shoulder and 3 in above the elbowOften easier for someone else to inject
ButtocksAsk your prescriber to show youIn insulin guidance; not listed on the Zepbound or Ozempic labels

Sources: MedlinePlus for the belly, thighs and upper arms; Embecta’s injection technique guide for the buttocks. The Zepbound and Ozempic labels list the abdomen, thigh and upper arm, and Zepbound’s label notes that the back of the upper arm should be injected by another person (Zepbound, Ozempic).

Skip any spot that is red, swollen, scarred, bruised or lumpy. The Egrifta WR instructions also rule out the belly button and “any hard bumps from previous injections” (Egrifta WR).

How to rotate

Embecta’s guide suggests dividing a site into four sections (or two halves for a thigh or buttock), using one section for a week and moving at least one finger’s width from the last injection each time. Ozempic’s label says to use a different injection site each week when injecting in the same body region.

A simple plan for a weekly injection:

  1. Picture your belly as four squares around the belly button: upper left, upper right, lower left, lower right.
  2. Use a different square each week, so each square gets one injection every 4 weeks.
  3. Within a square, move at least a finger’s width (about 1 in) from where you went last time.
  4. Write down where you injected, in a notebook or an injection log.

For daily injections, you’ll cover more ground, so use more than one body area and keep each new spot at least an inch from the last.

Why rotation matters: lipohypertrophy

Lipohypertrophy is a build-up of fatty tissue under skin that’s injected repeatedly. You may not see it, but you can often feel it as a soft or firm lump. The best evidence comes from insulin:

  • In a study of 430 people injecting insulin, 64% had lipohypertrophy. It was strongly linked to not rotating sites, and the risk rose when needles were reused more than 5 times. Of those who rotated correctly, only 5% had it (Blanco et al., 2013).
  • Insulin injected into these lumps was absorbed less, and far less predictably, than insulin injected into normal tissue (Famulla et al., 2016).
  • International injection recommendations say not to inject into these lesions, and that correct site rotation helps prevent them (Frid et al., 2016).

These studies are about insulin. Whether other injected peptides behave the same way hasn’t been studied as well, but rotating and using a new needle each time are simple habits that protect your skin either way.

Giving the injection

  1. Clean your hands and the site

    Wash your hands with soap and running water. Wipe the skin with an alcohol pad, moving outward from the spot, and let it dry.

  2. Pinch up the skin

    Gently pinch about an inch of skin and fat, not muscle, between your fingers.

  3. Insert the needle

    Insert it quickly, all the way in, at 90 degrees. Use 45 degrees if there’s very little fat at that spot.

  4. Inject and withdraw

    Release the pinch, push the plunger all the way, then pull the needle straight out. Press with clean gauze if there’s a little blood.

  5. Dispose of it

    Put the syringe straight into a sharps container. Never reuse or share needles.

These steps follow MedlinePlus. Follow your product’s own instructions where they differ.

The volume going in

Unit numbers tell you how much liquid you’re injecting under the skin. On a U-100 syringe, 20 units = 0.2 mL and 80 units = 0.8 mL. If a 10 mg vial is mixed with 2 mL (5 mg/mL), a prescribed amount of 1 mg is 0.2 mL, or 20 units. The same 1 mg from a vial mixed with 4 mL is 0.4 mL, or 40 units: twice the liquid. (Numbers for illustration only, not a dose.) The reconstitution calculator shows the volume for any vial. If your draws feel large, ask your pharmacist whether a different mix is appropriate.

Common mistakes

  • Always using the same “easy” spot.
  • Injecting into a lump, scar or bruise.
  • Injecting too close to the belly button. Stay at least 2 inches away.
  • Reusing needles. Reuse is linked to lipohypertrophy as well as infection.
  • Not letting the alcohol dry, which can sting.

Questions people ask

Where should I inject peptides?

Wherever your product’s label or prescriber says. For subQ products, that’s usually the belly, thighs or upper arms. Labels for some medicines allow only one area.

Where do you inject retatrutide?

Retatrutide is investigational and has no FDA-approved label, so there are no approved instructions for where or how to inject it; see its regulatory status. We don’t give injection instructions for unapproved products. If you’re taking part in a clinical trial, follow the study team’s instructions.

Is redness at the injection site normal?

Some soreness is expected, and mild reactions such as redness, itching or bruising can happen. In Egrifta WR’s trials, for example, 25% of people on the drug had injection-site reactions such as redness, itching, pain or bruising, against 14% on placebo. Contact your prescriber if you see redness, swelling, red streaks and a fever, which MedlinePlus lists as signs of infection.

Does the site change how well it works?

For semaglutide and tirzepatide, the FDA labels say similar exposure is achieved in the abdomen, thigh and upper arm (Ozempic, Zepbound). For other products, ask your pharmacist.

Sources

  1. Subcutaneous (SQ) injectionsMedlinePlus, U.S. National Library of Medicine, 2025 · Accessed Oct 15, 2026 (opens in a new tab)
  2. Injection technique guideEmbecta Corp., 2025 · Accessed Oct 15, 2026 (opens in a new tab)
  3. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetesDiabetes Metab, 2013 · Accessed Oct 15, 2026 (opens in a new tab)
  4. Insulin injection into lipohypertrophic tissue: blunted and more variable insulin absorption and action and impaired postprandial glucose controlDiabetes Care, 2016 · Accessed Oct 15, 2026 (opens in a new tab)
  5. New Insulin Delivery RecommendationsMayo Clin Proc, 2016 · Accessed Oct 15, 2026 (opens in a new tab)
  6. ZEPBOUND (tirzepatide) injection: prescribing informationEli Lilly and Company, via DailyMed (U.S. National Library of Medicine), 2026 · Accessed Oct 15, 2026 (opens in a new tab)
  7. OZEMPIC (semaglutide) injection: prescribing informationNovo Nordisk, via DailyMed (U.S. National Library of Medicine), 2026 · Accessed Oct 15, 2026 (opens in a new tab)
  8. EGRIFTA WR (tesamorelin) for injection: prescribing information and instructions for useTheratechnologies Inc., via DailyMed (U.S. National Library of Medicine), 2025 · Accessed Oct 15, 2026 (opens in a new tab)
Medical review in progressLast reviewed

Every medical and regulatory statement on this page links to a checkable source, listed above. Peptinote does arithmetic and education, not medical advice, and never sells or links to sellers of peptides.